The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Agilent Technologies (bioanalytical and electronic measurement instruments) is paying $10.94 in cash per share (a 31% premium) to acquire diagnostics and research tools maker Stratagene in a transaction valued at about $246mm based on 22.4mm Stratagene shares outstanding. (April)
Agilent plans to make Stratagene a division of its Life Sciences Solutions Unit. Stratagene, which started operations in 1984, serves...